Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AZN

Astrazeneca plc ADR

Jul 26 • 04:00PM ET

78.13

Dollar change -0.39
Percentage change -0.50	%

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: QQQ QQQM FVD DFIC PPH AVDE QYLD TQQQ QQEW DFAX

Scroll to Statements

Index	NDX	P/E	37.86	EPS (ttm)	2.06	Insider Own	0.02%	Shs Outstand	3.10B	Perf Week	-0.74%
Market Cap	242.25B	Forward P/E	16.52	EPS next Y	4.73	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-1.20%
Income	6.44B	PEG	2.80	EPS next Q	1.05	Inst Own	16.03%	Short Float	0.19%	Perf Quarter	4.13%
Sales	49.13B	P/S	4.93	EPS this Y	12.83%	Inst Trans	-2.08%	Short Ratio	1.41	Perf Half Y	16.58%
Book/sh	12.74	P/B	6.13	EPS next Y	15.50%	ROA	6.41%	Short Interest	5.80M	Perf Year	12.61%
Cash/sh	2.28	P/C	34.23	EPS next 5Y	13.50%	ROE	16.75%	52W Range	60.47 - 80.86	Perf YTD	16.01%
Dividend Est.	1.55 (1.98%)	P/FCF	24.77	EPS past 5Y	17.72%	ROI	9.51%	52W High	-3.38%	Beta	0.47
Dividend TTM	1.45 (1.86%)	Quick Ratio	0.69	Sales past 5Y	16.24%	Gross Margin	74.22%	52W Low	29.20%	ATR (14)	1.21
Dividend Ex-Date	Feb 22, 2024	Current Ratio	0.89	EPS Y/Y TTM	34.54%	Oper. Margin	17.50%	RSI (14)	48.30	Volatility	1.63% 1.30%
Employees	89900	Debt/Eq	0.85	Sales Y/Y TTM	10.45%	Profit Margin	13.11%	Recom	1.66	Target Price	90.00
Option/Short	Yes / Yes	LT Debt/Eq	0.71	EPS Q/Q	5.99%	Payout	73.87%	Rel Volume	1.43	Prev Close	78.52
Sales Surprise	2.32%	EPS Surprise	0.66%	Sales Q/Q	13.33%	Earnings	Jul 25 BMO	Avg Volume	4.12M	Price	78.13
SMA20	-0.07%	SMA50	-0.43%	SMA200	12.04%	Trades		Volume	5,874,389	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy	$75
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight

Show Previous Ratings

Today 12:54PM	FDA committee proposes overhaul of perioperative lung cancer trials (Pharmaceutical Technology)
12:25PM	3 Surprisingly Underrated Stocks to Buy Right Now (Motley Fool)
01:00AM	AstraZeneca CEO talks dual supply chain strategy (Yahoo Finance Video)
Jul-25-24 04:07PM	AstraZeneca Says It Has A 'Powerful' And Differentiated Approach To Obesity Treatment (Investor's Business Daily)
03:34PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
02:21PM	Loading…
02:21PM	US economy keeps growing, Astrazeneca CEO describes challenges: Catalysts (Yahoo Finance Video)
02:08PM	AstraZeneca CEO: We're building '2 supply chains' to avoid impact of US-China tensions (Yahoo Finance)
12:27PM	AstraZeneca CEO on revenue beat (CNBC TV)
11:48AM	Why AstraZeneca Stock Is Sliding Today (Motley Fool)
11:45AM	AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript (Motley Fool)
11:43AM	Why AstraZeneca's CEO isn't worried about costs (Yahoo Finance Video)
11:09AM	AstraZeneca Makes A Bearish Move Despite Quarterly Beat As FDA Panel Mulls Cancer Drug (Investor's Business Daily)
09:30AM	Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
09:28AM	NHS spending rules risk depriving Britain of new medicine, warns AstraZeneca boss (The Telegraph)
09:28AM	NHS rules risk depriving Britain of new medicine, warns AstraZeneca boss (The Telegraph)
09:20AM	Loading…
09:20AM	AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook (Investor's Business Daily)
09:19AM	AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines (Benzinga)
09:05AM	AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View (Zacks)
08:53AM	AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales (Investopedia)
07:33AM	Trials to watch: Four biologics concluding pivotal COPD trials (Clinical Trials Arena)
07:00AM	AstraZenecas H1 and Q2 2024 Financial Results (Business Wire)
05:06AM	Astrazeneca: Q2 Earnings Snapshot (Associated Press Finance)
04:07AM	AstraZeneca shares fall despite guidance raise as drugmaker warns on income (Investing.com)
02:50AM	AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations (The Wall Street Journal)
02:07AM	AstraZeneca raises profit outlook on strong medicines demand (Reuters)
Jul-24-24 06:08PM	Earnings from American & Southwest, Q2 GDP data: What to watch (Yahoo Finance Video)
10:13AM	AstraZeneca grows oncology portfolio with Pinetrees EGFR degrader (Pharmaceutical Technology)
Jul-23-24 03:04PM	Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants (Benzinga)
11:17AM	Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca (PR Newswire)
07:00AM	Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis (PR Newswire)
10:47AM	Loading…
Jul-22-24 10:47AM	Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings? (Zacks)
01:12AM	Enhertu set to become a blockbuster drug after outperforming Kadcyla (Clinical Trials Arena)
Jul-21-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
07:00AM	The race to develop the holy grail of weight-loss drugs (The Telegraph)
07:00AM	How a single daily pill could soon be the future of losing weight (The Telegraph)
Jul-18-24 10:45AM	AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy? (Zacks)
09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
Jul-17-24 06:15PM	Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts (Zacks)
Jul-16-24 09:45AM	Here's Why Astrazeneca (AZN) is a Strong Growth Stock (Zacks)
04:12AM	AstraZeneca completes Amolyt Pharma acquisition (Pharmaceutical Technology)
Jul-15-24 10:51AM	The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 (InvestorPlace)
10:45AM	Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
04:12AM	AstraZenecas Tagrisso gains approval in Canada for NSCLC (Pharmaceutical Technology)
Jul-10-24 03:22PM	7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns (InvestorPlace)
Jul-09-24 11:17AM	What The Quest For New Cholesterol Treatments Means For Novartis, Merck And Patients (Investor's Business Daily)
Jul-08-24 11:49PM	AstraZeneca PLC (AZN): Is This FTSE Dividend Stock a Good Buy Right Now? (Insider Monkey)
11:42PM	GSK plc (GSK): Is It the Best FTSE Dividend Stock to Buy According to Hedge Funds? (Insider Monkey)
12:34PM	10 Best FTSE Dividend Stocks To Buy Now (Insider Monkey)
07:29AM	EU approves AstraZeneca's Tagrisso combined with chemotherapy for EGFRm NSCLC (Pharmaceutical Business Review)
Jul-05-24 12:33PM	AstraZeneca & Aptamer partner to bolster targeted siRNA therapies (Clinical Trials Arena)
11:13AM	AstraZenecas Tagrisso plus chemotherapy wins EU approval for NSCLC (Pharmaceutical Technology)
10:22AM	AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC (Zacks)
Jul-02-24 11:00AM	AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use (Zacks)
10:42AM	3 Set-It-and-Forget-It Stocks for Lasting Financial Security (InvestorPlace)
04:12AM	EMA fast-tracks review of AstraZenecas sipavibart to stop Covid (Pharmaceutical Technology)
Jul-01-24 12:43PM	AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment (Benzinga)
11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-28-24 09:45AM	Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-26-24 02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
12:57PM	AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer (Zacks)
10:48AM	Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst (Yahoo Finance Video)
10:08AM	China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients (Benzinga)
05:12AM	AstraZenecas Tagrisso receives approval in Japan for lung cancer (Pharmaceutical Technology)
Jun-25-24 05:39PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:13AM	AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio (Clinical Trials Arena)
09:45AM	AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study (Benzinga)
07:00AM	IMFINZI (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial (Business Wire)
06:33AM	AstraZenecas trial of Imfinzi for lung cancer failed to meet primary endpoint (Clinical Trials Arena)
Jun-24-24 04:30PM	3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains (InvestorPlace)
10:33AM	Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success (InvestorPlace)
Jun-23-24 10:25AM	The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits (InvestorPlace)
Jun-22-24 07:15AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
Jun-21-24 03:52AM	AstraZenecas Truqap and Faslodex combo receives approval in EU (Pharmaceutical Technology)
Jun-20-24 04:16PM	Why Wall Street Is Chasing Ozempic Wannabes (The Wall Street Journal)
10:07AM	AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer (Zacks)
10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
Jun-19-24 01:09PM	From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data (PR Newswire)
07:13AM	AstraZenecas Truqap flops in Phase III triple negative breast cancer trial (Clinical Trials Arena)
Jun-18-24 10:56AM	AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study (Zacks)
10:19AM	Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment (Benzinga)
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-17-24 06:15PM	Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why (Zacks)
04:34PM	EHA 2024: AstraZenecas Calquence plus chemoimmunotherapy offers new standard for MCL (Pharmaceutical Technology)
11:27AM	AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use (Zacks)
07:00AM	IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer (Business Wire)
06:33AM	AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval (Pharmaceutical Technology)
06:32AM	AstraZeneca reports positive data from Phase III mantle cell lymphoma trial (Clinical Trials Arena)
06:00AM	3 Best Stocks to Buy From the Fantastic 5 (InvestorPlace)
01:32AM	AstraZeneca/Fibrogens Roxadustat FDA Review Further Delayed Following Unanticipated Advisory Committee Request (Clinical Trials Arena)
Jun-16-24 07:00AM	CALQUENCE (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial (Business Wire)
Jun-14-24 08:02AM	Adobe Inc. (NASDAQ:ADBE) Q2 2024 Earnings Call Transcript (Insider Monkey)
Jun-13-24 11:20AM	AstraZeneca CFO: 'We've come a long way in our oncology portfolio' (Yahoo Finance)
10:11AM	FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D (Zacks)
08:00AM	Why It's A New Day For COPD Patients And Regeneron, Sanofi, Verona Stocks (Investor's Business Daily)
04:32AM	FDA approves AstraZenecas Farxiga for paediatric T2D patients (Pharmaceutical Technology)
Jun-12-24 05:35PM	FARXIGA approved in the US for the treatment of pediatric type-2 diabetes (Business Wire)
08:13AM	AstraZeneca champions early kidney disease diagnosis with modelling data (Pharmaceutical Technology)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
Jun-11-24 12:58PM	Why AstraZeneca plc (NASDAQ:AZN) is Investors' One of Favorite International Dividend Stock? (Insider Monkey)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience